Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘KO-539’

What stood out at AACR20?

With every cancer conference ‘attended’ – this includes the ubiquitous virtual meetings these days – I usually ask myself a couple of simple, yet key questions:

  1. Did we see any promising new targets or agents in early development emerge?
  2. Did any one talk or concept stand out from everything else?

Sometimes the answer is an emphatic ‘no!’ to both, sometimes a ‘maybe’ to either, while at other times, one thing clearly stands out head and shoulders from the rest.

At AACR20, one particular development stood out clearly for me as being novel and innovative, as well as encouraging on several fronts, so let’s take a look at what’s different about it and why a KOL we interviewed was quietly excited…

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the first annual AACR virtual meeting subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Reflections on Day 1 of the AACR20 Virtual Meeting Part 1 – through a series of postcards

For cancer conferences, 2020 will be the year of the Virtual Meeting. The easy going world as we knew it just a few months ago is suddenly no longer.

We already know that many countries will be maintaining social distancing until at least the end of the year and perhaps longer into 2021. In others, a mandatory 14-day quarantine already in place for people entering the country will likely deter travel. Who wants to travel to a conference – even presuming it is going ahead – only to have to stay at home for 14 days afterwards?

The net result is that virtual meetings are likely here to stay for the duration and in the next few months we’ll see how organizations such as AACR, ASGCT, ASCO, and EHA produce them.

As of yesterday, there were 47,000 registered attendees for part 1 of the AACR virtual meeting, which is largely focused on early clinical trials.

What were some of the take-homes from Day 1 at the AACR20 virtual meeting?

We listened to many of the sessions and in this post share what stood out for us.

If you missed it, do check out our AACR20 Previews and ongoing coverage plus we will be rolling out additional in-depth posts once the meeting is over.

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the first annual AACR virtual meeting subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

First in class or best in class?

Which paths will ultimately lead to success with novel targeted therapies?

Ah this question often seems a perennial one to consider at AACR annual meetings – and this year is no different in this respect.

Personally, to me, it doesn’t really matter what you claim aspirationally based on preclinical or even early phase 1 dose escalation data because… a lot can happen between then and later registrational studies.

Think about it carefully – weak efficacy, wrong tumour selection or setting, adverse event profiles, even narrow therapeutic windows can all too soon interfere and play havoc like a wrecking ball with many a well intended clinical program, especially once you start looking at combination strategies!

No, it’s not as easy as it looks sometimes.

In our latest AACR Preview series, we take a look at a number of targeted agents in development, many aimed at novel targets at are not run-of-the mill…

To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the annual AACR meeting subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

A wet gloomy day in San Francisco was brightened up by some small biotech talks

San Francisco – The other day I mentioned that we could expect some cross pollination across several recent conferences and this latest post on Kura Oncology is one such example of that genre.

We’ve been following their story longitudinally for a while now and with a lot suddenly going on, 2020 could well turn out to be an crucial year for the company.

There is no doubt they have been pursuing a very focused precision medicine approach with tipifarnib and executing nicely on that strategy so far, but as more indications and additional pipeline agents move into the clinic do the same principles still apply?

To find out, we interviewed a couple of their senior executives and discussed both current progress as well as where they are headed…

To learn more from our oncology coverage and get a heads up on our latest commentary from the JPM and ASH annual meetings, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!